Pyxis Oncology Inc
Research Pyxis Oncology Inc (PYXS) on Bullrun: market cap USD 181.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPYXS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 181.20M
- Financial periodFY2025
- RevenueUSD 13.86M
- Revenue growth-14.2%
- Net income-USD 79.62M
- Free cash flow-USD 63.51M
- Gross margin82.8%
Valuation Snapshot
latest market cap is USD 181.20M.
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors;
Frequently asked questions
What is Pyxis Oncology Inc's market cap?
Pyxis Oncology Inc's market capitalization is USD 181.20M.
What does Pyxis Oncology Inc do?
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to...